TY - JOUR
T1 - Cytomegalovirus in the transplant setting
T2 - Where are we now and what happens next? A report from the International CMV Symposium 2021
AU - The International CMV Symposium Faculty
AU - Kotton, Camille N.
AU - Torre-Cisneros, Julián
AU - Aguado, José Maria
AU - Alain, Sophie
AU - Baldanti, Fausto
AU - Baumann, Gabriele
AU - Boeken, Udo
AU - de la Calle, Maria
AU - Carbone, Javier
AU - Ciceri, Fabio
AU - Comoli, Patrizia
AU - Couzi, Lionel
AU - Danziger-Isakov, Lara
AU - Fernández-Ruiz, Mario
AU - Girmenia, Corrado
AU - Grossi, Paolo Antonio
AU - Hirsch, Hans H.
AU - Humar, Atul
AU - Kamar, Nassim
AU - Kotton, Camille
AU - Ljungman, Per
AU - Malagola, Michele
AU - Mira, Estefania
AU - Mueller, Nicolas
AU - Sester, Martina
AU - Teng, Chieh Lin Jerry
AU - Torre-Cisneros, Julian
AU - Ussetti, Piedad
AU - Westall, Glen
AU - Wolf, Dana
AU - Zamora, Marty
N1 - Publisher Copyright:
© 2022 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
PY - 2022/12
Y1 - 2022/12
N2 - The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV. (Figure presented.).
AB - The CMV Symposium in September 2021 was an international conference dedicated to cytomegalovirus (CMV) infection after solid organ or hematopoietic stem cell transplantation. This review provides an overview of the presentations given by the expert faculty, supplemented with educational clinical cases. Topics discussed include CMV epidemiology and diagnosis, the burden of CMV infection and disease, CMV-specific immunity and management of CMV in transplant settings. Major advances in the prevention and treatment of CMV in the past decade and increased understanding of CMV immunity have led to improved patient outcomes. In the future, management algorithms may be individualized based on the transplant recipient's immune profile, which will mark the start of a new era for patients with CMV. (Figure presented.).
KW - cellular therapy
KW - cytomegalovirus immunoglobulin (CMVIG)
KW - hematopoietic stem cell transplant
KW - prophylaxis
KW - solid organ transplant
KW - treatment
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85142050914&partnerID=8YFLogxK
U2 - 10.1111/tid.13977
DO - 10.1111/tid.13977
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 36271650
AN - SCOPUS:85142050914
SN - 1398-2273
VL - 24
JO - Transplant Infectious Disease
JF - Transplant Infectious Disease
IS - 6
M1 - e13977
ER -